Fair value · TAKEDA PHARMACEUTICAL CO LTD (TAK) · updated 2026-10-03 · from 20-F FY2026
TAKEDA PHARMACEUTICAL CO trades at $17.86. We are not reading assumptions out of that price: financials are filed in JPY; our prices are in USD, so these methods need a conversion we do not yet publish.
Everything below is unaffected: the filed statements, the filing they came from, and TAK’s growth history are all as reported.
The filing behind these numbers
TAKEDA PHARMACEUTICAL CO LTD- Revenue
- JPY 4.51T
- Diluted EPS
- JPY -96.75
- Free cash flow
- JPY 865.4B
- operating cash flow − capital expenditure
- Diluted shares
- 1.58B
- weighted average
20-F FY2026 · fiscal year ended 2026-03-31 · filed 2026-06-17 · accession 0001395064-26-000177
Open this filing on sec.govNeed TAK data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.